financetom
Business
financetom
/
Business
/
SingTel's interim net profit falls 42%, sees higher EBIT for FY25
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SingTel's interim net profit falls 42%, sees higher EBIT for FY25
Nov 12, 2024 9:56 PM

(Reuters) -Singapore Telecommunications (SingTel) on Wednesday reported a 42% slump in its first-half net profit due to the absence of a S$1.2 billion ($896.59 million) gain it had logged through the merger of Telkomsel a year earlier.

Southeast Asia's largest telecom firm also said it expects its earnings before interest and tax (EBIT) to grow by low double digits for fiscal 2025.

Last year, Telkomsel, the Indonesian associate of SingTel, agreed to merge with its parent's IndiHome broadband arm to expand into Indonesia's fixed broadband market.

The firm's top boss shed some light on SingTel's progress with developing revenue streams to harness artificial intelligence and data centres.

"Both NCS and Nxera (SingTel's data centre brand) have a critical role to play in advancing AI adoption in the region and are continuing to invest in AI infrastructure and capabilities to better serve enterprise and governments," the group's Chief Executive Officer Yuen Kuan Moon said.

"We will continue scaling NCS and building out Nxera's data centres which will commence operations from mid-2025 to meet increasing demand," Moon added.

SingTel's Australian unit Optus, currently embroiled in a legal battle with the country's competition watchdog, reported interim operating revenue of A$4.02 billion ($2.62 billion), in line with A$4.02 billion reported a year ago.

The company said net profit for the six months ended Sept. 30 was S$1.23 billion, as compared to S$2.14 billion last year and missing a Visible Alpha estimate of S$1.37 billion. 

The company declared an interim dividend of 7 Singapore cents per share, higher than the 5.2 Singapore cents per share declared a year earlier.

($1 = 1.3384 Singapore dollars)

($1 = 1.5321 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing's Chief of Commercial Planes Quality Elizabeth Lund to Retire; Doug Ackerman Named Successor
Boeing's Chief of Commercial Planes Quality Elizabeth Lund to Retire; Doug Ackerman Named Successor
Nov 11, 2024
02:26 PM EST, 11/11/2024 (MT Newswires) -- Boeing's ( BA ) chief of commercial airplanes quality Elizabeth Lund is retiring next month after an extended tenure of more than 33 years, according to an internal memo seen Monday by MT Newswires. Doug Ackerman, who is currently vice president of supply chain and fabrication quality, has been named as Lund's successor....
Ispire Technology Shares Fall After Company Posts Lower Fiscal Q1 Results
Ispire Technology Shares Fall After Company Posts Lower Fiscal Q1 Results
Nov 11, 2024
02:17 PM EST, 11/11/2024 (MT Newswires) -- Ispire Technology ( ISPR ) shares were down more than 4% in recent trading Monday after the company reported lower fiscal Q1 results. The company reported a fiscal Q1 loss of $0.10 per diluted share, widening than a loss of $0.02 a year earlier. One analyst polled by Capital IQ expected a loss...
National Bank Reviews Doman Building's Q3
National Bank Reviews Doman Building's Q3
Nov 11, 2024
02:25 PM EST, 11/11/2024 (MT Newswires) -- Doman Building's third quarter revenue hit $663.1 million, beating National Bank's $638.3 million estimate (Street: $616.7 million). Adj. EPS came to $0.18, above National's $0.13 forecast and the Street's $0.14. National Bank has increased its target to $12.50 (was $12) on 11.5x 2026e EPS, equivalent to a 9.7% FCF yield. We rate DBM...
CERo Therapeutics Stock Is Soaring Monday: What's Going On?
CERo Therapeutics Stock Is Soaring Monday: What's Going On?
Nov 11, 2024
CERo Therapeutics Holdings, Inc. ( CERO ) shares are moving higher Monday after the company presented preclinical data for its lead compound. The Details: CERo Therapeutics ( CERO ) announced preclinical data showing the capability of lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.   “We have long contended that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved